Advertisement
Advertisement
DFTX
D
Definium Therapeutics, Inc. Common Shares
22.05
USDSponsored
-1.15
-4.96%
May 08, 16:00 UTC -4
Closed
Pre-Market
22.13
+0.08
+0.36%
DFTX Earnings Reports
Positive Surprise Ratio
DFTX beat 0 of 3 last estimates.
0%
Next Report
Date of Next Report
Jul 29, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.52
Implied change from Q1 26 (Revenue/ EPS)
--
/-26.76%
Implied change from Q2 25 (Revenue/ EPS)
--
/+4.00%
Definium Therapeutics, Inc. Common Shares earnings per share and revenue
On May 07, 2026, DFTX reported earnings of -0.71 USD per share (EPS) for Q1 26, missing the estimate of -0.50 USD, resulting in a -41.43% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.96% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.52 USD, with revenue projected to reach -- USD, implying an decrease of -26.76% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Quoin Pharmaceuticals, Ltd. - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.96
Actual
-$1.77
Surprise
+9.93%
FAQ
What were Definium Therapeutics, Inc. Common Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Definium Therapeutics, Inc. Common Shares reported EPS of -$0.71, missing estimates by -41.43%, and revenue of $0.00, 0% as expectations.
How did the market react to Definium Therapeutics, Inc. Common Shares's Q1 2026 earnings?
The stock price moved down -4.96%, changed from $23.20 before the earnings release to $22.05 the day after.
When is Definium Therapeutics, Inc. Common Shares expected to report next?
The next earning report is scheduled for Jul 29, 2026.
What are the forecasts for Definium Therapeutics, Inc. Common Shares's next earnings report?
Based on --
analysts, Definium Therapeutics, Inc. Common Shares is expected to report EPS of -$0.52 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement